Latest news
FDA Reviews Clesrovimab for Second-Season RSV Prevention in High-Risk Children - Patient Care OnlinePatient Care Online · Sat, 08 Aug 2026 02:54:59 GMTFindings support clesrovimab as option to protect children entering second RSV season - HealioHealio · Fri, 07 Aug 2026 18:28:31 GMTClesrovimab shows comparable safety to palivizumab in high-risk infants across 2 RSV seasons - Contemporary PediatricsContemporary Pediatrics · Fri, 07 Aug 2026 17:56:30 GMTFDA Accepts Merck's Application to Expand Enflonsia into Second RSV Season - BioPharm InternationalBioPharm International · Thu, 06 Aug 2026 16:59:38 GMTFDA Accepts sBLA for Clesrovimab-cfor in Second RSV Season - hcplive.comhcplive.com · Thu, 06 Aug 2026 16:30:47 GMTFDA accepts application to expand clesrovimab-cfor use to high-risk children in second RSV season - Contemporary PediatricsContemporary Pediatrics · Thu, 06 Aug 2026 14:18:27 GMTU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season - Business WireBusiness Wire · Thu, 06 Aug 2026 10:45:00 GMTChildren May Benefit From Second Season Clesrovimab - MedscapeMedscape · Wed, 29 Jul 2026 10:07:47 GMT